KRAS inhibitors
Drugs targeting KRAS mutations, such as sotorasib and adagrasib.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 45, 43, 40, 37, 35.
New guidelines and consensus this year
All papers from the last 12 months
1,010 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLCGenes Dis2027 JanPMID 42761382Review
- An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancerOncoimmunology2026 Dec 31PMID 42141809
- Ligand-based pharmacophore modeling and molecular dynamics driven discovery of novel MEK1 inhibitors targeting KRAS signalling pathwayJ Mol Graph Model2026 DecPMID 42777666
- Discovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cellsJ Enzyme Inhib Med Chem2026 DecPMID 42274165
- Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinomaAnn Med2026 DecPMID 41987491Review
- Design, synthesis and biological evaluation of novel KRAS-G12D inhibitorsJ Enzyme Inhib Med Chem2026 DecPMID 41645749
- Non-coding small RNAs buffer protein interactions to prevent oncogenic aggregation: structural dampening of aberrant PPIs by RNARNA Biol2026 DecPMID 41605259
- 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancreatic ductal adenocarcinomaEur J Med Chem2026 Nov 15PMID 42574799
- Targeting conventionally intractable cancer-driving proteins: What has been achieved recently?Eur J Med Chem2026 Nov 5PMID 42364458Review
- Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenariosLung Cancer2026 NovPMID 42731561
More oncology trends
All specialties →Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Cell therapy in solid tumours
CAR-T, TIL and TCR-T therapies for solid tumours.
CDK4/6 inhibitors in breast cancer
Palbociclib, ribociclib and abemaciclib in hormone receptor-positive breast cancer.
Radioligand therapy
Radioactive drugs that target tumour receptors, such as lutetium-177 PSMA.
Key point: Most international guidelines endorse 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer after prior ARPI and taxane chemotherapy.
Multi-cancer early detection
Blood tests that screen for many cancers at once.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
KRAS[tiab] AND (inhibitor*[tiab] OR sotorasib[tiab] OR adagrasib[tiab] OR divarasib[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.